Clinical trial
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab…
NCT00113490 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00113490 |
|---|---|
| Title | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children |
| Official title | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), After Dosing for a Second Season in Children Who Previously Received MEDI-524 in Protocol MI-CP104 |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Motavizumab Administration for a Second Season for RSV Prophylaxis |
| Intervention type | Biological |
| Interventions | motavizumab (MEDI-524), palivizumab 15 mg/kg |
| Enrollment | 136 |
| Start date | May 1, 2005 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Jun 9, 2005 |
| Last update posted | May 22, 2013 |
| Countries | Brazil, Chile |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: